Chemomab Therapeutics Ltd. (CMMB): who owns it and who trades it
As of Nov 16, 2026, CMMB insiders reported 2 open-market sales worth $6.5K and 2 purchases worth $20.2K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Neil Harris Cohen (Director), with $6.5K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Chemomab Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, CMMB insiders reported $20.2K of open-market purchases and $6.5K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Neil Harris Cohen | Director | Sale | 1,000 | $2.80 | $2.8K | Form 4 |
| Aug 27, 2026 | Neil Harris Cohen | Director | Sale | 1,304 | $2.85 | $3.7K | Form 4 |
| May 29, 2026 | George Adi Mor | CEO | Purchase | 4,878 | $2.05 | $10K | Form 4 |
| May 29, 2026 | George Adi Mor | CEO | Purchase | 4,926 | $2.08 | $10.2K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| George Adi Mor | Chief Executive Officer, Director | $20.2K | – | May 29, 2026 |
| Neil Harris Cohen | Director | – | $6.5K | Aug 28, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CMMB short interest
5,139 CMMB shares are sold short. Over the last 12 reports the number of shares short went down 87%.
As of Oct 30, 2026, 5,139 CMMB shares were sold short, down 63.0% from the report before. At the average daily volume of 48,290 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5,139 | – | -63% | 48,290 | 1.0 |
| Oct 15, 2026 | 13,889 | – | +32% | 43,029 | 1.0 |
| Sep 30, 2026 | 10,544 | – | -87% | 215,472 | 1.0 |
| Sep 15, 2026 | 81,947 | – | -20% | 83,213 | 1.0 |
| Aug 31, 2026 | 102,705 | – | -9% | 139,834 | 1.0 |
| Aug 14, 2026 | 113,157 | – | -27% | 58,882 | 1.9 |
| Jul 31, 2026 | 155,604 | – | +15% | 71,908 | 2.2 |
| Jul 15, 2026 | 134,909 | 0.02% | -6% | 506,716 | 1.0 |
| Jun 30, 2026 | 143,144 | 0.02% | +7% | 34,378 | 4.2 |
| Jun 15, 2026 | 134,275 | 0.02% | +247% | 49,633 | 2.7 |
| May 29, 2026 | 38,648 | 0.01% | -3% | 50,866 | 1.0 |
| May 15, 2026 | 39,649 | 0.01% | -16% | 45,269 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Chemomab Therapeutics financials
Famous investors that hold CMMB
2 of the 50 well-known investors we track reported holding CMMB in their latest 13F filing. The largest position is Ken Griffin's, worth $131K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 109,763 | $131K | 0.0% | +15% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 10,328 | $12.3K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CMMB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | Scipher Medicine Corp | 13D | 10.4% |
| Nov 10, 2026 | Scipher Medicine Corp | 13D | 10.4% |
Questions about Chemomab Therapeutics Ltd. (CMMB) stock
Are CMMB insiders buying or selling?
In the last 12 months, CMMB insiders reported 2 open-market purchases worth $20.2K and 2 sales worth $6.5K. The latest trade was on Aug 28, 2026. See every trade.
What is the short interest in CMMB?
As of Oct 30, 2026, 5,139 CMMB shares were sold short, down 63.0% from the report before. At the average daily volume of 48,290 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold CMMB?
2 of the 50 well-known investors we track reported CMMB in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $131K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.